NCT05312216尚未招募2 期
A Study on the Efficiency and Safety of Durvalumab Plus Lenvatinib as First-line Treatment for Unresectable Hepatocellular Carcinoma: an Open, Single Arm, Phase II Clinical Trial
Zhejiang University1 个研究点 分布在 1 个国家目标入组 25 人开始时间: 2023年4月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 25
- 试验地点
- 1
- 主要终点
- Objective response rate (ORR)
研究概览
简要总结
This is a phase II, open-label study to evaluate the efficacy and safety of Durvalumab plus Lenvatinib as first-line treatment in patients with unresectable hepatocellular carcinoma.
详细描述
This single-arm, open-label, prospective phase II clinical trial was designed to evaluate the efficacy and safety of Durvalumab plus Lenvatinib as first-line treatment in patients with unresectable hepatocellular carcinoma. The primary endpoint is the objective response rate (ORR) according to RECIST v1.1. Safety evaluation will be taken according to CTCAE v5.0. Disease control rate (DCR), duration of response (DOR), progression-free survival (PFS) and overall survival (OS) are secondary endpoints. Multi-omics analysis will be performed to identify potential biomarkers for treatment response.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects volunteer to participate in the study and sign the informed consent before enrollment.
- •18-80 years of age.
- •ECOG score of 0-
- •Primary liver cancer with a pathological diagnosis of hepatocellular carcinoma.
- •Child-Pugh grade A (5-6 points).
- •BCLC C stage or BCLC B stage not suitable/refused for locoreginal treatments.
- •Tumor volume ≤ 50% of the total liver volume.
- •Without prior systemic therapy and unwilling to receive standard systemic therapy or unsuitable for standard systemic therapy.
- •At least one measurable lesion as defined by RECIST v1.1 criteria.
- •Patients infected with hepatitis virus should receive antiviral therapy regularly.
- •No history of drug allergy.
- •Function of vital organs in accordance with the following requirements (no blood components, cell growth factors and other corrective therapeutic agents are allowed within 14 days prior to enrolment): Absolute neutrophil count ≥ 1.5 x 10^9/L; Platelets ≥ 80 x 10^9/L; Haemoglobin ≥ 90 g/L; Serum albumin ≥ 35 g/L; Thyrotropin (TSH) ≤ 1×ULN (if abnormal, FT3 and FT4 levels should be examined at the same time, if FT3 and FT4 levels are normal, enrollment is allowed); Serum bilirubin ≤ 1.5 x ULN (within 7 days prior to first dose); ALT and AST ≤ 5 x ULN (within 7 days prior to first dose); International normalised ratio (INR) ≤ 1.5 or prothrombin time (PT) ≤ 1.5 x ULN; Serum creatinine ≤ 1.5 x ULN.
- •Female patients who are non-surgically sterilised or of childbearing age are required to use contraception (e.g. IUD, pill or condom) during and for 3 months after the end of the treatment; female patients of childbearing age who are non-surgically sterilised must have a negative serum or urine HCG test within 72h prior to study entry; and must be non-lactating; male patients whose partners are women of childbearing age should be tested during the trial and for 3 months after the last dose. Male patients whose partners are women of childbearing age should use an effective method of contraception during the trial and for 3 months after the last dose.
排除标准
- •Patients with any active autoimmune disease or history of autoimmune disease (e.g. the following but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enterocolitis, autoimmune hepatitis, pituitary inflammation, vasculitis, nephritis, hyperthyroidism, vitiligo. Patients with complete remission of asthma in childhood who do not require any intervention in adulthood may be included, but those require bronchodilators cannot be included.
- •Patients who are on immunosuppressive drugs, or require systemic hormone therapy for immunosuppression purposes (doses >10 mg/day of prednisone or other isotonic hormones) and who continue to use them within 2 weeks prior to enrollment.
- •Receiving systemic therapy previously or other anti-cancer treatments (e.g. radiofrequency ablation, interventional therapy, radiotherapy, etc.)
- •Patients with a known history of central neural system metastases or hepatic encephalopathy.
- •Patients with clinically symptomatic ascites requiring puncture or drainage or those who have received ascites drainage within the previous 3 months.
- •Patients with hypertension that is not well controlled by antihypertensive medication (systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg).
- •Having clinical cardiac symptoms or disease not well controlled, such as (1) NYHA class 2 or higher heart failure (2) unstable angina pectoris (3) myocardial infarction within 1 year (4) clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention (5) QTc > 450 ms (men); QTc > 470 ms (women).
- •With abnormal coagulation (INR > 2.0, PT > 16s), bleeding tendency or on thrombolytic or anticoagulant therapy. Prophylactic use of low-dose aspirin or low molecular heparin is allowed.
- •Patients had clinically significant bleeding symptoms or a clear bleeding tendency within the 3 months prior to enrollment.
- •Having arterial/venous thrombotic events within the 6 months prior to enrollment.
- •With hereditary or acquired bleeding and thrombotic tendencies.
- •With urine protein ≥ ++ and confirmed by 24-hour urine protein amount > 1.0 g.
- •Patients with active infection, unexplained fever ≥ 38.5°C within 7 days prior to the first dose, or baseline white blood cell count > 15 x 10^9/L.
- •Patient with a congenital or acquired immune deficiency (e.g. HIV infection).
- •Patient with other malignancies (except cured basal cell carcinoma of the skin and carcinoma in situ of the cervix) within the previous 3 years or concurrently.
- •Patients who have other factors that could affect the outcome of the study or force the termination of the study, such as alcoholism, substance abuse, other serious illnesses (including psychiatric illness) requiring comorbid treatment.
研究组 & 干预措施
Durvalumab plus Lenvatinib
Experimental
Durvalumab is a human IgG1 κ monoclonal antibody that inhibits binding of PD-L1 to its receptors PD-1 and CD80.
Lenvatinib is a multi- kinase inhibitor of VEGF receptors 1 to 3, FGF receptors 1 to 4, PDGFRa, RET, and KIT.
干预措施: Durvalumab plus Lenvatinib (Drug)
结局指标
主要结局
Objective response rate (ORR)
时间窗: up o one year
The proportion of patients who had tumor response evaluated as CR or PR according to RECIST v1.1 during study.
次要结局
- Disease control rate (DCR)(up to one year)
- Duration of response (DOR)(up to one year)
- Progression-free survival (PFS)(up to one year)
- Overall survival (OS)(up to two years)
- Adverse events (AEs)(up to two years)
研究者
TingBo Liang
The chairman of the First Affiliated Hospital of Zhejiang
Zhejiang University
研究点 (1)
Loading locations...
相似试验
终止
2 期
A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple MyelomaMultiple MyelomaNCT02807454Celgene37
招募中
不适用
Durvalumab and Lenvatinib in Participants With Locally Advanced and Metastatic Hepatocellular Carcinoma ( Dulect2020-1 )Liver CarcinomaLiver Transplant ComplicationsNCT04443322RenJi Hospital20
Unknown
不适用
Durvalumab and Lenvatinib in Participants With Advanced and Recurrent Endometrial CarcinomaEndometrial CancerNCT04444193Shanghai First Maternity and Infant Hospital20
招募中
2 期
Durvalumab and Lenvatinib With or Without Chemotherapy in First-Line Treatment of Advanced Biliary Tract CancerBiliary Tract NeoplasmsImmunotherapyNCT05935579Peking Union Medical College Hospital40
Unknown
2 期
Phase II Study of Durvalumab in Combination With Lenalidomide in Relapsed/Refractory NK-T-cell LymphomaLYMPHOMANCT03054532Singapore General Hospital22